JP2026016543A5 - - Google Patents

Info

Publication number
JP2026016543A5
JP2026016543A5 JP2025178768A JP2025178768A JP2026016543A5 JP 2026016543 A5 JP2026016543 A5 JP 2026016543A5 JP 2025178768 A JP2025178768 A JP 2025178768A JP 2025178768 A JP2025178768 A JP 2025178768A JP 2026016543 A5 JP2026016543 A5 JP 2026016543A5
Authority
JP
Japan
Prior art keywords
domain
seq
sequence numbers
treg
antigen recognition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025178768A
Other languages
English (en)
Japanese (ja)
Other versions
JP2026016543A (ja
Filing date
Publication date
Priority claimed from GBGB1912515.2A external-priority patent/GB201912515D0/en
Application filed filed Critical
Publication of JP2026016543A publication Critical patent/JP2026016543A/ja
Publication of JP2026016543A5 publication Critical patent/JP2026016543A5/ja
Pending legal-status Critical Current

Links

JP2025178768A 2019-08-30 2025-10-23 改変された制御性t細胞 Pending JP2026016543A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1912515.2 2019-08-30
GBGB1912515.2A GB201912515D0 (en) 2019-08-30 2019-08-30 Engineered regulatory T cell
JP2022513373A JP2022546457A (ja) 2019-08-30 2020-08-28 改変された制御性t細胞
PCT/GB2020/052076 WO2021038249A1 (en) 2019-08-30 2020-08-28 Engineered regulatory t cell

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022513373A Division JP2022546457A (ja) 2019-08-30 2020-08-28 改変された制御性t細胞

Publications (2)

Publication Number Publication Date
JP2026016543A JP2026016543A (ja) 2026-02-03
JP2026016543A5 true JP2026016543A5 (cg-RX-API-DMAC7.html) 2026-05-21

Family

ID=68207135

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513373A Pending JP2022546457A (ja) 2019-08-30 2020-08-28 改変された制御性t細胞
JP2025178768A Pending JP2026016543A (ja) 2019-08-30 2025-10-23 改変された制御性t細胞

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022513373A Pending JP2022546457A (ja) 2019-08-30 2020-08-28 改変された制御性t細胞

Country Status (10)

Country Link
US (1) US20230134301A1 (cg-RX-API-DMAC7.html)
EP (1) EP4021484A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022546457A (cg-RX-API-DMAC7.html)
KR (1) KR20220051390A (cg-RX-API-DMAC7.html)
CN (1) CN114585730A (cg-RX-API-DMAC7.html)
AU (1) AU2020338290A1 (cg-RX-API-DMAC7.html)
CA (1) CA3148676A1 (cg-RX-API-DMAC7.html)
GB (1) GB201912515D0 (cg-RX-API-DMAC7.html)
IL (1) IL290830A (cg-RX-API-DMAC7.html)
WO (1) WO2021038249A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202217541D0 (en) * 2022-11-24 2023-01-11 Quell Therapeutics Ltd Recombinant receptor
EP4442322A1 (en) 2023-04-06 2024-10-09 Medizinische Hochschule Hannover Liver-specific car for use against immunologic rejection
CN118001381B (zh) * 2024-01-24 2025-04-22 首都医科大学附属北京地坛医院 一种药物组合物及应用
WO2026027876A1 (en) * 2024-07-29 2026-02-05 Quell Therapeutics Limited Chimeric antigen receptor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
EP2523686A2 (en) * 2010-01-14 2012-11-21 Glaxo Group Limited Liver targeting domain antibodies
GB201108236D0 (en) * 2011-05-17 2011-06-29 Ucl Business Plc Method
CN105713881B (zh) * 2014-12-04 2019-12-06 科济生物医药(上海)有限公司 双靶向gpc3和asgpr1的转基因免疫效应细胞及其应用
CA2974998C (en) * 2015-02-12 2022-04-26 Takara Bio Inc. Chimeric antigen receptors
WO2017021911A1 (en) * 2015-08-04 2017-02-09 Glaxosmithkline Intellectual Property Development Limited Combination treatments and uses and methods thereof
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药(上海)有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CA3042179A1 (en) * 2016-10-31 2018-05-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 gene
CN111684061B (zh) * 2018-01-19 2024-07-30 美天施生物科技有限两合公司 表达嵌合抗原受体的调节性t细胞
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells

Similar Documents

Publication Publication Date Title
US10647770B2 (en) Therapeutic agent for autoimmune diseases comprising PD-1 agonist
JP2025183279A5 (cg-RX-API-DMAC7.html)
JP2022061992A5 (cg-RX-API-DMAC7.html)
JP6908591B2 (ja) Il2rベータ/共通ガンマ鎖抗体
JP6719477B2 (ja) 抗tim−3抗体
JP2022531911A5 (cg-RX-API-DMAC7.html)
US10259874B2 (en) Anti-TIM-3 antibodies
JP2022546457A5 (cg-RX-API-DMAC7.html)
US20220251221A1 (en) Il2rbeta/common gamma chain antibodies
JP2022543387A5 (cg-RX-API-DMAC7.html)
JP2023519099A5 (cg-RX-API-DMAC7.html)
JP2021530236A5 (cg-RX-API-DMAC7.html)
WO2017020812A1 (zh) 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
JP2012501670A5 (cg-RX-API-DMAC7.html)
JP2023551027A5 (cg-RX-API-DMAC7.html)
JP2021511041A5 (cg-RX-API-DMAC7.html)
CN116789820A (zh) 一种新型免疫调节剂的开发和应用
JP7461875B2 (ja) 病気の症状の治療又は予防に使用するための抗アドレノメデュリン(adm)バインダー
JP2024507540A5 (cg-RX-API-DMAC7.html)
CN116836269A (zh) 抗呼吸道合胞病毒的单克隆抗体及其应用
RS63580B1 (sr) Humanizovana antitela protiv clever-1 i njihova primena
CN108276492A (zh) 抗pd-l1单克隆抗体及其应用
CN108314734A (zh) 抗pd-1单克隆抗体及其应用
CN116854820B (zh) Pd-1非阻断性清除抗体及其用途
TWI910636B (zh) 特異性結合cll1的抗體及其製法和應用